Clinical Trials Browser

Phase 2 × Lymphoma × B3(Fv)-PE38KDEL recombinant immunotoxin × Clear all

NCT00080535 2018-01-29

Anti-Tac(Fv)-PE38 (LMB-2) to Treat Cutaneous T-Cell Lymphomas

Phase 2 Completed

10 enrolled 10 charts

DermatologicLymphoid

Lymphoma, Neoplasms, Lymphoma, T-Cell, Cutaneous